Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity.

Fatty acid amide hydrolase (FAAH) is an integral membrane enzyme that degrades the fatty acid amide family of signaling lipids, including the endocannabinoid anandamide. Genetic or pharmacological inactivation of FAAH leads to analgesic, anti-inflammatory, anxiolytic, and antidepressant phenotypes in rodents without showing the undesirable side effects observed with direct cannabinoid receptor agonists, indicating that FAAH may represent an attractive therapeutic target for treatment of pain, inflammation, and other central nervous system disorders. However, the FAAH inhibitors reported to date lack drug-like pharmacokinetic properties and/or selectivity. Herein we describe piperidine/piperazine ureas represented by N-phenyl-4-(quinolin-3-ylmethyl)piperidine-1-carboxamide (PF-750) and N-phenyl-4-(quinolin-2-ylmethyl)piperazine-1-carboxamide (PF-622) as a novel mechanistic class of FAAH inhibitors. PF-750 and PF-622 show higher in vitro potencies than previously established classes of FAAH inhibitors. Rather unexpectedly based on the high chemical stability of the urea functional group, PF-750 and PF-622 were found to inhibit FAAH in a time-dependent manner by covalently modifying the enzyme's active site serine nucleophile. Activity-based proteomic profiling revealed that PF-750 and PF-622 were completely selective for FAAH relative to other mammalian serine hydrolases. We hypothesize that this remarkable specificity derives, at least in part, from FAAH's special ability to function as a C(O)-N bond hydrolase, which distinguishes it from the vast majority of metabolic serine hydrolases in mammals that are restricted to hydrolyzing esters and/or thioesters. The piperidine/piperazine urea may thus represent a privileged chemical scaffold for the synthesis of FAAH inhibitors that display an unprecedented combination of potency and selectivity for use as potential analgesic and anxiolytic/antidepressant agents.

[1]  B. Cravatt,et al.  Activity-based protein profiling: the serine hydrolases. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[2]  B. Cravatt,et al.  Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[3]  Raymond C Stevens,et al.  Structural Adaptations in a Membrane Enzyme That Terminates Endocannabinoid Signaling , 2002, Science.

[4]  Stephen P. H. Alexander,et al.  A spectrophotometric assay for fatty acid amide hydrolase suitable for high-throughput screening. , 2005, Biochemical pharmacology.

[5]  J. Brioni,et al.  Fatty acid amide hydrolase inhibitors display broad selectivity and inhibit multiple carboxylesterases as off-targets , 2007, Neuropharmacology.

[6]  Dale L Boger,et al.  Discovering potent and selective reversible inhibitors of enzymes in complex proteomes , 2003, Nature Biotechnology.

[7]  D. Piomelli,et al.  Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models , 2006, British journal of pharmacology.

[8]  Helge Weissig,et al.  Functional interrogation of the kinome using nucleotide acyl phosphates. , 2007, Biochemistry.

[9]  B. Cravatt,et al.  Comparative characterization of a wild type and transmembrane domain-deleted fatty acid amide hydrolase: identification of the transmembrane domain as a site for oligomerization. , 1998, Biochemistry.

[10]  Baohong Zhang,et al.  High-resolution functional proteomics by active-site peptide profiling. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[11]  A. Burlingame,et al.  Chemical Approaches for Functionally Probing the Proteome* , 2002, Molecular & Cellular Proteomics.

[12]  J. G. Robertson,et al.  Mechanistic basis of enzyme-targeted drugs. , 2005, Biochemistry.

[13]  D. Boger,et al.  Catalysis of the CC-1065 and duocarmycin DNA alkylation reaction: DNA binding induced conformational change in the agent results in activation. , 1997, Bioorganic & medicinal chemistry.

[14]  I. Ollmann,et al.  Inhibition of Oleamide Hydrolase Catalyzed Hydrolysis of the Endogenous Sleep-Inducing Lipid cis-9-Octadecenamide , 1996 .

[15]  J. Crystal,et al.  An endocannabinoid mechanism for stress-induced analgesia , 2005, Nature.

[16]  B. Cravatt,et al.  Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia , 2004, Pain.

[17]  B. Cravatt,et al.  Structure and function of fatty acid amide hydrolase. , 2005, Annual review of biochemistry.

[18]  A. Arnaud,et al.  Study of the amidase signature group. , 1996, Biochimica et biophysica acta.

[19]  C. Fowler,et al.  Inhibitors of fatty acid amide hydrolase reduce carrageenan‐induced hind paw inflammation in pentobarbital‐treated mice: comparison with indomethacin and possible involvement of cannabinoid receptors , 2005, British journal of pharmacology.

[20]  Alan Saghatelian,et al.  Functional disassociation of the central and peripheral fatty acid amide signaling systems. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[21]  B. Cravatt,et al.  Chemical and mutagenic investigations of fatty acid amide hydrolase: evidence for a family of serine hydrolases with distinct catalytic properties. , 1999, Biochemistry.

[22]  B. Cravatt,et al.  Fatty acid amide hydrolase competitively degrades bioactive amides and esters through a nonconventional catalytic mechanism. , 1999, Biochemistry.

[23]  B. Cravatt,et al.  The putative endocannabinoid transport blocker LY2183240 is a potent inhibitor of FAAH and several other brain serine hydrolases. , 2006, Journal of the American Chemical Society.

[24]  Stephen P. Mayfield,et al.  Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides , 1996, Nature.

[25]  D. Boger,et al.  Potent and selective alpha-ketoheterocycle-based inhibitors of the anandamide and oleamide catabolizing enzyme, fatty acid amide hydrolase. , 2007, Journal of medicinal chemistry.

[26]  S. Gaetani,et al.  An anorexic lipid mediator regulated by feeding , 2001, Nature.

[27]  A. Shevchenko,et al.  Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. , 1996, Analytical chemistry.

[28]  Robert A. Copeland,et al.  Enzymes: A Practical Introduction to Structure, Mechanism, and Data Analysis , 1996 .

[29]  S. Henriksen,et al.  Characterization of the sleep-wake patterns in mice lacking fatty acid amide hydrolase. , 2004, Sleep.

[30]  J. Yates,et al.  Method to correlate tandem mass spectra of modified peptides to amino acid sequences in the protein database. , 1995, Analytical chemistry.

[31]  C. Fowler,et al.  The palmitoylethanolamide family: a new class of anti-inflammatory agents? , 2002, Current medicinal chemistry.

[32]  A. Saghatelian,et al.  Reversible Inhibitors of Fatty Acid Amide Hydrolase That Promote Analgesia: Evidence for an Unprecedented Combination of Potency and Selectivity , 2004, Journal of Pharmacology and Experimental Therapeutics.

[33]  S. Gaetani,et al.  Modulation of anxiety through blockade of anandamide hydrolysis , 2003, Nature Medicine.

[34]  Nasreen S Jessani,et al.  Enzyme activity profiles of the secreted and membrane proteome that depict cancer cell invasiveness , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[35]  B. Cravatt,et al.  Molecular characterization of human and mouse fatty acid amide hydrolases. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[36]  T. Cassano,et al.  Correction for Gobbi et al., Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[37]  J. Rosenblum,et al.  Inhibitor focusing: direct selection of drug targets from proteomes using activity-based probes. , 2003, Assay and drug development technologies.

[38]  R. Lerner,et al.  Chemical characterization of a family of brain lipids that induce sleep. , 1995, Science.

[39]  B. Cravatt,et al.  Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality , 2007, Psychopharmacology.

[40]  Benjamin F. Cravatt,et al.  Potent and Selective α-Ketoheterocycle-Based Inhibitors of the Anandamide and Oleamide Catabolizing Enzyme, Fatty Acid Amide Hydrolase , 2007 .

[41]  D. Gibson,et al.  Isolation and structure of a brain constituent that binds to the cannabinoid receptor. , 1992, Science.

[42]  B. Cravatt,et al.  Evidence for Distinct Roles in Catalysis for Residues of the Serine-Serine-Lysine Catalytic Triad of Fatty Acid Amide Hydrolase* , 2003, Journal of Biological Chemistry.

[43]  A. Duranti,et al.  The Fatty Acid Amide Hydrolase Inhibitor URB597 (Cyclohexylcarbamic Acid 3′-Carbamoylbiphenyl-3-yl Ester) Reduces Neuropathic Pain after Oral Administration in Mice , 2007, Journal of Pharmacology and Experimental Therapeutics.

[44]  Sandy J. Wilson,et al.  Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms , 2006 .

[45]  B. Cravatt,et al.  Mechanism of carbamate inactivation of FAAH: implications for the design of covalent inhibitors and in vivo functional probes for enzymes. , 2005, Chemistry & biology.

[46]  D. Boger,et al.  Discovery of a potent, selective, and efficacious class of reversible alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase effective as analgesics. , 2005, Journal of medicinal chemistry.

[47]  D. N. Perkins,et al.  Probability‐based protein identification by searching sequence databases using mass spectrometry data , 1999, Electrophoresis.

[48]  J. Burbaum,et al.  Direct visualization of serine hydrolase activities in complex proteomes using fluorescent active site‐directed probes , 2001, Proteomics.